Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Athena Diagnostics

Athena Diagnostics
1989 FOUNDED
M&A STATUS
101-200 EMPLOYEES
M&A LATEST DEAL TYPE
3 FINANCING ROUNDS
Description

Developer and provider of proprietary molecular diagnostic and immunodiagnostic tests and services. The company provides advanced neurological diagnostic assays. It provides diagnosis on peripheral nerve disorders, neurogenetic disorders, Alzheimer's disease, paraneoplastic syndromes, movement disorders, neuromuscular disorders, and ataxia.

Formerly Known As
Genica Pharmaceuticals
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Laboratory Services (Healthcare)
Other Industries
Other Healthcare Services
Primary Office
  • Four Biotech Park
  • 377 Plantation Street
  • Worcester, MA 01605
  • United States

+1 (508) 000-0000

Athena Diagnostics Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Athena Diagnostics‘s full profile, request access.

Request full access to PitchBook

Athena Diagnostics Competitors (1)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
0000000 0000000000 Private Equity-Backed Frankfurt a.M., Germany 000000000000
To view this company’s complete list of competitors, request access »

Athena Diagnostics Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Athena Diagnostics‘s full profile, request access.

Request full access to PitchBook

Athena Diagnostics Executive Team (6)

Name Title Board
Seat
Contact
Info
Jeffrey Weisberg Chief Financial Officer & Senior Vice President, Financial Operations
Joseph Sterk Director, Esoteric Neurology Marketing
Glen Gershon Vice President, Operations

3 Former Executives

You’re viewing 3 of 6 executives. Get the full list »